855-853-4760

customerservice@arevapharma.com

Erlotinib

Erlotinib

The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.

Products Information

RX PRODUCTNDC#STRENGTHSIZEPRODUCT CLASSADMINISTRATIONCASE SIZE
Erlotinib
59923-725-30 25 mg 30Antineoplastic Oral N.A
Erlotinib 59923-726-30 100 mg 30AntineoplasticOral N.A
Erlotinib 59923-727-30 150 mg 30AntineoplasticOral N.A
WholesalerErlotinib 25mg Erlotinib 100mg Erlotinib 150mg
AmerisourceBergen 102360331023603210236031
Cardinal568064056806575680665
McKesson157357515736251573641